Treatment-related adverse events reported in ≥10% of patients in the overall study population, or in ≥2 patients at grade ≥3 severity.
pneumonia, TRAEs, leukopenia, syncope, lymphopenia, inappropriate antidiuretic hormone secretion, presyncope, any-grade, hypokalemia
PNEUMONIA, FEBRILE NEUTROPENIA, ESSENTIAL HYPERTENSION, LEUKOPENIA, DIABETES MELLITUS, LYMPHOPENIA, ABDOMINAL INFECTION, SKIN HEMORRHAGE, HYPERAMYLASEMIA, INAPPROPRIATE ANTIDIURETIC HORMONE SECRETION
Grade 3 essential hypertension, hypokalemia, lipase increased, liver function test abnormal, presyncope, skin hemorrhage, and grade 4 blood creatinine phosphokinase increased, diabetes mellitus, and inappropriate antidiuretic hormone secretion were reported in one patient each in the overall part A population. Grade 3 abdominal infection, blood bilirubin increased, pneumonia and grade 4 blood creatinine increased, febrile neutropenia, leukopenia, and lymphopenia were reported in one patient each in the part B R/R DLBCL population. Grade 3 gamma-glutamyl transferase increased, hyperamylasemia, and syncope were reported in one patient each in the part C population. Source data are provided as a source data file. Details﻿ of TRAEs and all-cause TEAEs occurring at any-grade and grade 3–5 severity are shown in Supplementary Tables 